Celcuity (NASDAQ:CELC) Stock Price Expected to Rise, Citizens Jmp Analyst Says

Celcuity (NASDAQ:CELC) had its price objective upped by Citizens Jmp from $160.00 to $177.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s target price points to a potential upside of 100.48% from the company’s current price.

CELC has been the subject of a number of other research reports. Wells Fargo & Company reduced their price objective on shares of Celcuity from $183.00 to $166.00 and set an “overweight” rating for the company in a research report on Wednesday, June 3rd. Needham & Company LLC reiterated a “buy” rating and set a $157.00 target price on shares of Celcuity in a research report on Friday, May 15th. Stifel Nicolaus set a $150.00 target price on Celcuity in a research report on Monday, May 4th. HC Wainwright increased their target price on Celcuity from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Wall Street Zen cut Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Eleven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $155.18.

Celcuity Stock Down 3.5%

Shares of Celcuity stock opened at $88.29 on Wednesday. The company has a market cap of $4.31 billion, a P/E ratio of -22.64 and a beta of 0.16. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. Celcuity has a one year low of $13.47 and a one year high of $151.02. The firm has a fifty day moving average of $109.02 and a two-hundred day moving average of $110.95.

Celcuity (NASDAQ:CELC) last released its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.10. On average, analysts forecast that Celcuity will post -3.69 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. This trade represents a 57.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the sale, the director directly owned 65,000 shares in the company, valued at $9,144,200. This trade represents a 27.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.33% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Celcuity

Several hedge funds and other institutional investors have recently bought and sold shares of the company. NEA Management Company LLC grew its holdings in Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after purchasing an additional 1,391,300 shares during the last quarter. Avoro Capital Advisors LLC acquired a new position in shares of Celcuity during the 4th quarter worth $310,302,000. Soleus Capital Management L.P. boosted its position in shares of Celcuity by 17.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after buying an additional 437,696 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Celcuity by 10.7% in the 4th quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after buying an additional 220,386 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Celcuity by 126.6% in the 4th quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after buying an additional 914,887 shares in the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Citizens JMP raised its price target on Celcuity to $177 from $160 and kept an “outperform” view, signaling confidence in the company’s upside after the approval. Citizens Jmp Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price
• Positive Sentiment: The FDA approved REVTORPYK for advanced HR+/HER2- breast cancer, a major regulatory milestone that could open the door to Celcuity’s first commercial product and future revenue. Celcuity Gets FDA Approval for Breast Cancer Drug
• Positive Sentiment: Multiple reports highlighted the approval as a potentially transformative event for Celcuity, with some analysts suggesting the drug’s success could make the company an attractive acquisition target for larger pharmaceutical firms. With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
• Neutral Sentiment: Celcuity held a discussion and transcript on its FDA approval and commercial launch plans, which may provide more detail on timing and launch execution but does not by itself change the fundamental story. Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans Transcript
• Negative Sentiment: Investors were also focused on rollout risks, including a delayed launch timeline and tolerability concerns, which appear to be outweighing the approval news in the near term. Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
• Negative Sentiment: Several reports noted that despite the FDA win, concerns about commercialization timing and competitive pressure are weighing on the stock. Celcuity Shares Down, FDA Approval Outweighed by Timeline Questions for Breast-Cancer Treatment

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.